Esperion Therapeutics (NASDAQ:ESPR) Sees Strong Trading Volume – Here’s What Happened

Posted by Brian Himes on Jun 1st, 2026

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) saw strong trading volume on Monday . 11,491,280 shares were traded during trading, an increase of 31% from the previous session’s volume of 8,739,462 shares.The stock last traded at $3.1350 and had previously closed at $3.13.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Tuesday, April 21st. Cantor Fitzgerald cut Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. Jefferies Financial Group cut Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. Piper Sandler cut Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. Finally, HC Wainwright cut Esperion Therapeutics from a “buy” rating to a “neutral” rating and set a $3.16 price objective on the stock. in a research note on Friday, May 1st. One analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $5.54.

Check Out Our Latest Analysis on Esperion Therapeutics

Esperion Therapeutics Stock Up 0.2%

The stock has a market capitalization of $807.05 million, a P/E ratio of -52.25, a PEG ratio of 2.54 and a beta of 0.91. The company has a 50 day moving average of $2.62 and a 200-day moving average of $3.12.

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) last posted its earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.08). The company had revenue of $80.10 million during the quarter, compared to the consensus estimate of $84.52 million. Esperion Therapeutics had a net margin of 0.12% and a negative return on equity of 0.14%. Equities analysts forecast that Esperion Therapeutics, Inc. will post 0.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Esperion Therapeutics

Several large investors have recently made changes to their positions in ESPR. Sivia Capital Partners LLC acquired a new stake in shares of Esperion Therapeutics in the second quarter valued at approximately $25,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Esperion Therapeutics in the third quarter valued at approximately $29,000. R Squared Ltd acquired a new stake in shares of Esperion Therapeutics in the third quarter valued at approximately $33,000. Kestra Advisory Services LLC acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at approximately $35,000. Finally, KFG Wealth Management LLC acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at approximately $37,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

(Get Free Report)

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.